In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs

Anti-Cancer Drugs

Volumn 11, Issue 7, 2000, Pages 573-578

  Hiramatsu, Hisakazu Paul ^a   Kikuchi, Yoshihiro ^b   Seto, Hiroshi ^a   Nagata, Ichiro ^b  

^a Seto Hospital   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Anticancer drugs; Cisplatin; Combined effects; Human endometrial cancer cell lines; Irinotecan; Peak plasma concentrations

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PIRARUBICIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENDOMETRIUM CANCER; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DIVISION; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0033800755     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200008000-00009     Document Type: Article

References (24)

1. Postoperative external irradiation and prognostic parameters in stage 1 endometrial carcinoma
2. Limited endometrial carcinoma: Adjuvant therapy
3. Postoperative radiotherapy for endometrial carcinoma stage 1. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in the southeast Netherlands
4. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: A preliminary analysis
5. Postoperative adjuvant cisplatin, doxorubicin, and cyclophopsphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma
6. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma
7. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer
8. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group Study
9. Topotecan in the treatment of gynecologic cancer
10. Establishment of eighteen clones of Ishikawa cells
11. Establishment of a cell line of human endometrial adenocarcinoma in vitro
12. In vitro growth characteristics and chemosensitivity of endometrial cancer using a soft agar clonogenic assay
13. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs
14. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
15. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix
16. Taxol is active in platinum-resistant endometrial adenocarcinoma
17. Annual report on the results of treatment in gynecologic cancer
18. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammineplatinum(II) after intensive prior therapy
19. Cisplatin chemotherapy for disseminated endometrial cancer
20. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide
21. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide
22. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy
23. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma
24. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells